vericiguat

11/01/2022 - "Vericiguat, an sGC stimulator, was shown to improve outcomes in patients with HFrEF in the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. "
09/01/2020 - "[Vericiguat-new treatment option for patients with heart failure : Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA)]."
05/26/2023 - "The efficacy of vericiguat for heart failure: A meta-analysis of randomized controlled trials."
03/01/2023 - "This study aimed to investigate the safety and efficacy of vericiguat in patients with heart failure (HF). "
05/26/2023 - "This meta-analysis aimed to explore the efficacy of vericiguat for heart failure. "

01/01/2019 - "Conclusions VITALITY-HFpEF is the first trial designed to assess the efficacy of vericiguat in patients with HFpEF using the Kansas City Cardiomyopathy Questionnaire physical limitation score as a novel primary end point. "
01/01/2017 - "The pre-specified exploratory endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score improved in the vericiguat 10 mg arm by mean 19.3 ± 16.3 points [median 19.8 (interquartile range 10.4-30.7)] from baseline (mean difference from placebo 9.2 points). "
01/01/2019 - "Exploratory post hoc analyses from a prior trial showed that vericiguat can improve patient-relevant domains of the Kansas City Cardiomyopathy Questionnaire, especially the physical limitation score. "
01/01/2022 - "We examined the effects of vericiguat compared with placebo in patients with heart failure with reduced ejection fraction enrolled in VICTORIA (Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction) on health status outcomes measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and evaluated whether clinical outcomes varied by baseline KCCQ score. "
01/01/2023 - "The authors examined the association between: 1) patient-reported frailty, measured by the Fried frailty phenotype, Kansas City Cardiomyopathy Questionnaire Physical Limitation Score (KCCQ-PLS), 6-minute walking distance (6MWD), and other baseline characteristics; 2) baseline frailty compared with KCCQ-PLS and 24-week 6MWD; 3) frailty and changes in KCCQ-PLS and 6MWD; and 4) vericiguat and frailty at 24 weeks. "

01/01/2022 - "Vericiguat Improves Aortic Wave Reflection Parameters in a New Preclinical Model of Hypertension."
11/01/2021 - "Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?"
11/01/2022 - "riociguat, vericiguat) have been extensively used in pulmonary artery hypertension (PAH) and heart failure (HF). "
01/01/2020 - "The studies reviewed include clinical trials on the efficacy and safety of alirocumab (Study in Participants with Homozygous Familial Hypercholesterolemia [ODYSSEY HoFH]) and evinacumab in the treatment of homozygous familial hypercholesterolemia (HoFH); Evaluating the Efficacy of E-cigarettes for Smoking Cessation (E3); the use of renal denervation in the treatment of hypertension (SPYRAL HTN-OFF MED PIVOTAL); and the assessment of vericiguat in the treatment of heart failure (A Study of Vericiguat in Participants with Heart Failure with Reduce Ejection Fraction [VICTORIA]). "

01/01/2023 - "Vericiguat reduces electrical and structural remodeling in a rabbit model of atrial fibrillation."
01/01/2021 - "Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial."
01/01/2021 - "We evaluated the relation between baseline and new-onset atrial fibrillation (AF) and outcomes, and assessed whether vericiguat modified the likelihood of new-onset AF in patients with worsening heart failure (HF) with reduced ejection fraction in VICTORIA. "
01/01/2017 - "Patients (N = 477; 48% women; mean age 73 ± 10 years; baseline atrial fibrillation 40%) were randomized within 4 weeks of HF hospitalization (75%) or outpatient treatment with intravenous diuretics for HF (25%) to vericiguat (n = 384) or placebo (n = 93). "
05/01/2023 - "Our review suggests that vericiguat was better in preventing all causes of death, cardiovascular death, and hospitalizations due to heart failure irrespective of the atrial fibrillation status of the patients and was even beneficial for patients with NT-proBNP levels up to 8000 pg/ml. The safety of the vericiguat, according to our review, is not up to the standards, especially with a higher dosage of vericiguat. "

12/01/2022 - "Initial experience of vericiguat add-on therapy upon fantastic four medical therapy in a patient with systolic heart failure."
12/01/2022 - "The VICTORIA trial demonstrated that vericiguat, a novel oral soluble guanylate cyclase stimulator, improved mortality and morbidity in patients with systolic heart failure, receiving conventional anti-heart failure medications. "
08/01/2023 - "Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction."
12/01/2022 - "Clinical implication of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with systolic heart failure receiving "fantastic four" including sodium-glucose cotransporter 2 inhibitors remains uncertain. "